Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Analyst Recommendations on JOHNSON & JOHNSON
10/13JOHNSON & JOHNSON : Credit Suisse gives a Buy rating
MD
08/20J&J, Biotech Firm In $6.5 Billion Deal J&J Agrees to Buy Biotech Company -- W..
DJ
07/21Pharma Companies Split on Coronavirus Vaccine Pricing Plans
DJ
07/16JOHNSON & JOHNSON : Beats Analysts' Profit Expectations for 2Q
DJ
05/28GENMAB : Darzalex Meets Main Endpoint in Light-Chain Amyloidosis Study
DJ
02/05Drugmakers see long road ahead in coronavirus vaccine race
RE
2019J&J recalls 33,000 bottles of baby powder as FDA finds asbestos in sample
RE
2019JOHNSON & JOHNSON : Goldman Sachs maintains a Buy rating
MD
2019JOHNSON & JOHNSON : Credit Suisse reiterates its Buy rating
MD
2019JOHNSON & JOHNSON : J&J warns of hit from generic drugs in third quarter, shares..
RE
2019JOHNSON & JOHNSON : J&J warns of hit from generic drugs in third quarter, shares..
RE
2019JOHNSON & JOHNSON : Credit Suisse keeps its Buy rating
MD
2019JOHNSON & JOHNSON : RBC reaffirms its Buy rating
MD
2019GLOBAL MARKETS LIVE : LVMH, Burberry, Facebook, Tesla…
2019Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide
RE
2019Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
RE
2019Emerging markets to fuel Smith & Nephew revenue growth in 2019
RE
2018Biotech incubator taps investors through in-house brokerage
RE
2018U.S. insurers grilled on exposure to $4.7 billion J&J talc verdict
RE
2018J&J nears diabetes device exit with $2.1 bln LifeScan sale
RE
2018Johnson & Johnson nears diabetes device exit with $2.1 billion LifeScan sale
RE
2018Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2017European shares reverse early losses, DAX immune to political worries
RE
2017FTSE weighed down by housebuilders and strong pound
RE
2017U.S. dollar up, yield curve flat, on inflation; stocks rise
RE
2017U.S. dollar up, yield curve flat, on inflation; stocks rise
RE
2017Germany's Merck hires JP Morgan to sell consumer health
RE
2017Nestle plan hailed as only the start of Schneider's shake-up
RE
2017Nestle plan hailed as only the start of Schneider's shake-up
RE
2017Stroke drug Xarelto, plastics lift Bayer earnings
RE
2017Morgan Stanley bags big spots on Unilever, Reckitt deals - sources
RE
2017Johnson & Johnson refills drug cabinet with $30 billion Actelion deal
RE
2017Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
2016Pfizer to start shipping biosimilar version of J&J's Remicade in November
RE
2016Moody's reviews Microsoft credit rating for cut after LinkedIn deal
RE
2016Cheap oil smudges Exxon's long-held sterling credit rating
RE
2016No quick fix seen for Novartis's troubled Alcon unit
RE
2015Big business on winning side in U.S. top court's major rulings
RE
2015CELLTRION : J&J cuts full-year forecast due to strong dollar
RE
2015AbbVie CEO defends Pharmacyclics deal to sceptical investors
RE
2015Cardinal to buy J&J vascular technology unit Cordis for $1.9 billion
RE
2014Johnson Matthey optimistic for full-year
RE
2014Sodexo cuts sales growth forecast due to contract delays
RE
2014Bayer wins Merck & Co's $14 billion consumer unit auction
RE
2014Bayer wins Merck & Co's $14 billion consumer unit auction
RE
2014Johnson Matthey says outlook brighter, names new CEO
RE
2013Factbox - U.S. biotech shares outpace broader stock market
RE
2013Elan rejects Royalty bid as grossly undervaluing its prospects
RE
2013Elan rejects Royalty bid as grossly undervaluing its prospects
RE
2013Ahead of reform, medical care slowdown hits companies
RE
2013Analysis - Ahead of reform, medical care slowdown hits U.S. companies
RE
2013J&J stake sale clouds Royalty bid for Elan
RE
2013Elan bid to fend off Royalty handed boost in buyback
RE
2013Elan offers special dividend to fend off Royalty
RE
2012Reckitt trumps Bayer with $1.4 billion bid for Schiff
RE
2012Pfizer settles foreign bribery case with U.S. government
RE
2012J&J hit by strong dollar, CEO eyes pruning units
RE
2012JOHNSON & JOHNSON : now expects Synthes deal to boost profit
RE
2012New Amgen CEO must win investors with payouts, deals
RE
2012Coty woos Avon shareholders, outlines financing
RE
2009JOHNSON & JOHNSON : Wall Street lower as J&J misses sales forecast
RE
2009JOHNSON & JOHNSON : Stock futures lower after J&J misses sales forecasts
RE
2009JOHNSON & JOHNSON : Stock futures edge higher ahead of earnings
RE
2009GLOBAL SH : Global stocks near two-week highs, dollar wilts
RE
2009JOHNSON & JOHNSON : J&J profit falls but beats forecasts
RE
2009GOLDMAN S : Stock futures rise before Goldman results, retail sales
RE
2009GOLDMAN S : Stock futures flat before retail sales, Goldman
RE
2009ABBOTT LABS : Abbott loses sales momentum
RE
2009MOODY'S CORP : Moody's strips Berkshire Hathaway of top rating
RE
2009MOODY'S CORP : Moody's cuts GE rating two notches, outlook stable
RE
2009MOODY'S CORP : Moody's says could cut GE's triple-A credit rating
RE
2009PFIZER : to buy Wyeth for $68 billion
RE
1  2Next
Upcoming event on JOHNSON & JOHNSON